{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:11:51Z","timestamp":1787587911282,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3404104"],"award-info":[{"award-number":["2023YFC3404104"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273128"],"award-info":[{"award-number":["82273128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230097"],"award-info":[{"award-number":["82230097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.apsb.2026.03.029","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:53:53Z","timestamp":1773942833000},"page":"3907-3919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["RAD51-targeting small molecule degrader sensitizes BRCA-proficient prostate cancer cells to PARP inhibitors via synthetic lethality"],"prefix":"10.1016","volume":"16","author":[{"given":"Yanlin","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.03.029_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.apsb.2026.03.029_bib2","article-title":"Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance","volume":"6","author":"Tian","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.029_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.apsb.2026.03.029_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.apsb.2026.03.029_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41585-022-00680-4","article-title":"Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations","volume":"20","author":"Rajwa","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.apsb.2026.03.029_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2023.03.038","article-title":"PARP inhibitors for prostate cancer: tangled up in PROfound and PROpel (and TALAPRO-2) blues","volume":"84","author":"Beije","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.apsb.2026.03.029_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.03.029_bib8","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.029_bib9","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.029_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2020.09.024","article-title":"Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: reconstructing prespecified endpoints for cohort B from the phase 3 PROfound trial of olaparib","volume":"79","author":"Stopsack","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.apsb.2026.03.029_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2022.08.014","article-title":"Double-stranded DNA binding function of RAD51 in DNA protection and its regulation by BRCA2","volume":"82","author":"Halder","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.03.029_bib12","doi-asserted-by":"crossref","first-page":"31941","DOI":"10.1074\/jbc.272.51.31941","article-title":"RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.029_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1097-2765(01)00175-7","article-title":"Role of BRCA2 in control of the RAD51 recombination and DNA repair protein","volume":"7","author":"Davies","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.03.029_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1\u2013BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.029_bib16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41586-025-08749-x","article-title":"BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments","volume":"640","author":"Lahiri","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.029_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41586-024-07196-4","article-title":"Cryo-EM structures of RAD51 assembled on nucleosomes containing a DSB site","volume":"628","author":"Shioi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.029_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.029_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2024.07.004","article-title":"RAD51 protects abasic sites to prevent replication fork breakage","volume":"84","author":"Hanthi","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.03.029_bib20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2026.03.029_bib21","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-22-3335","article-title":"RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer","volume":"29","author":"Compadre","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.029_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trecan.2018.11.001","article-title":"A road map to personalizing targeted cancer therapies using synthetic lethality","volume":"5","author":"Parameswaran","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2026.03.029_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.03.029_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/jm301565b","article-title":"An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity","volume":"56","author":"Budke","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib25","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1093\/nar\/gks353","article-title":"RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells","volume":"40","author":"Budke","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.03.029_bib26","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1021\/acs.jmedchem.5b01762","article-title":"Development of small molecules that specifically inhibit the D-loop activity of RAD51","volume":"59","author":"Lv","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib27","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1021\/jm1002974","article-title":"Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide","volume":"53","author":"Nomme","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib28","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1039\/D3SC03331G","article-title":"A recombinant approach for stapled peptide discovery yields inhibitors of the RAD51 recombinase","volume":"14","author":"Pantelejevs","year":"2023","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2026.03.029_bib29","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1093\/nar\/gkp200","article-title":"DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange","volume":"37","author":"Ishida","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.03.029_bib30","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/cb100428c","article-title":"Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening","volume":"6","author":"Huang","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.029_bib31","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1021\/jm201173g","article-title":"Inhibition of homologous recombination in human cells by targeting RAD51 recombinase","volume":"55","author":"Huang","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2015.04.021","article-title":"Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors","volume":"96","author":"Zhu","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/emmm.201201760","article-title":"A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia","volume":"5","author":"Zhu","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2026.03.029_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejmech.2019.01.008","article-title":"RAD51\/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells","volume":"165","author":"Roberti","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib35","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/acs.jmedchem.9b01526","article-title":"Synthetic lethality in pancreatic cancer: discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib","volume":"63","author":"Bagnolini","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib36","series-title":"United States patent US No. WO 2019\/051465A1","author":"Castro","year":"2019"},{"key":"10.1016\/j.apsb.2026.03.029_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2021.02.006","article-title":"A small-molecule inhibitor of the BRCA2\u2013RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death","volume":"28","author":"Scott","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.029_bib38","doi-asserted-by":"crossref","first-page":"32931","DOI":"10.1074\/jbc.274.46.32931","article-title":"Expression of BRC repeats in breast cancer cells disrupts the BRCA2\u2013RAD51 complex and leads to radiation hypersensitivity and loss of G2\/M checkpoint control","volume":"274","author":"Chen","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.03.029_bib39","article-title":"Differential impact of cytoplasmic vs. nuclear RAD51 expression on breast cancer progression and patient prognosis","volume":"64","author":"Wang","year":"2024","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2026.03.029_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073740","article-title":"RAD51 inhibition induces R-Loop formation in early G1 phase of the cell cycle","volume":"22","author":"Nascakova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.029_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3892\/or.2017.5724","article-title":"The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma","volume":"38","author":"Chen","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.apsb.2026.03.029_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90039-X","article-title":"Mice lacking P21CIP1\/WAF1 undergo normal development, but are defective in G1 checkpoint control","volume":"82","author":"Deng","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.029_bib43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.029_bib44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.029_bib45","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.029_bib46","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.03.029_bib47","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.029_bib48","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/j.apsb.2021.01.002","article-title":"Cyclin-dependent kinases-based synthetic lethality: evidence, concept, and strategy","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.029_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.apsb.2020.06.003","article-title":"Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.029_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.029_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.029_bib52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.apsb.2023.09.003","article-title":"Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies","volume":"14","author":"Peng","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.029_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2026.03.029_bib54","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","article-title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","volume":"119","author":"Hodgson","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.03.029_bib55","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:50:12Z","timestamp":1783018212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2211383526001887"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.029","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAD51-targeting small molecule degrader sensitizes BRCA-proficient prostate cancer cells to PARP inhibitors via synthetic lethality","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}